Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Cytosorbents Corp | ctso-20201231xex32d2.htm |
| EX-31.2 - EXHIBIT 31.2 - Cytosorbents Corp | ctso-20201231xex31d2.htm |
| EX-31.1 - EXHIBIT 31.1 - Cytosorbents Corp | ctso-20201231xex31d1.htm |
| EX-23.1 - EXHIBIT 23.1 - Cytosorbents Corp | ctso-20201231xex23d1.htm |
| EX-21.1 - EXHIBIT 21.1 - Cytosorbents Corp | ctso-20201231xex21d1.htm |
| 10-K - 10-K - Cytosorbents Corp | ctso-20201231x10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of CytoSorbents Corporation (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dr. Phillip Chan, President and Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
Dated: March 9, 2021 | By: | /s/ Dr. Phillip P. Chan |
| | Dr. Phillip P. Chan |
| | Chief Executive Officer |
| | (Principal Executive Officer) |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form with the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.